© 2018 Miraculo Inc. All Rights Reserved
Analgesic Effect of the Synthetic Cannabinoid CT-3 on Chronic Neuropathic Pain
A Randomized Controlled Trial
Cannabinoids are found in the marijuana plant (cannabis sativa) and are said to be effective in pain management from pain symptoms such as multiple sclerosis, diabetic neuropathy, peripheral neuropathy and nausea and vomiting. A cannabinoid is one of a great collection of complex chemical compounds that naturally occur in the body and operates on major cannabinoid receptors in cells that mediates neurotransmitter release in the brain. Cannabinoids for these receptors include the endocannabinoid system, that are produced in the body by animals, the phytocannabinoids in cannabis and some other plants, and synthetic cannabinoids. The main cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. Cannabidiol (CBD) is another main constituent of the plant and produces a non psychotic effect. This paper describes the analgesic effect a selective synthetic cannabinoid has on chronic neuropathic nerve pain.
Selective synthetic cannabinoids have therapeutic potential in treating chronic pain
This study was conducted to evaluate the therapeutic effectiveness and safety of CT-3 in chronic neuropathic pain in animals. A randomized, placebo-mediated, double-blind crossover trial took place in Germany from May-September 2002. Twenty-one patients (8 women and 13 men) aged 29 to 65 years (mean, 51 years) who had a clinical evaluation and reviewed consistent with chronic neuropathic pain (for at least 6 months) with hyperalgesia (n = 21) and allodynia (n = 7). People were randomized to two 7-day treatment orders in a crossover structured experiment. The results from this experiment suggested that the selective synthetic cannabinoids CT-3 was efficient in treating chronic pain in humans.
Endogenous cannabinoids may have an anti inflammatory role in treating chronic pain
1′,1′Dimethylheptyl-Δ8-tetrahydrocannabinol-11-oic acid (CT-3) possibly held the effectiveness to treat neuropathic pain and muscle stiffness without the psychotropic faults of cannabis. CT-3 is a synthetic analog of tetrahydrocannabinol (THC)-11-oic acid, one of the endogenous transformation offspring of THC, in which a dimethylheptyl side chain is switched for the pentyl side chain.In other words, CT-3 was discovered to be a strong anti-inflammatory, therapeutic, and antiallodynic agent without psychoactive abilities in healing nerve fibers. Although the exact neurobiological method is not transparent, some truths lie within that apart from the famous cannabinoid receptors (CB1 and CB2), 1 or more unfounded cannabinoid receptors are cahoots with the regulation of the therapeutic and anti-inflammatory impacts of CT-3. More so, additional research indicates potential postreceptor mechanisms, including inducing of eicosanoid synthesis and down-regulation of cyclooxygenase 2. Recent results suggest that the peroxisome proliferator–activated receptor γ (PPARγ) may act as an intracellular receptor for CT-3.The triggering of PPARγ is directly linked to common causes of anti-inflammatory and antitumor functions.